🇺🇸 FDA
Patent

US 12171750

Isoxazoline parasiticide formulations and methods for treating blepharitis

granted A61KA61K31/42A61K31/422

Quick answer

US patent 12171750 (Isoxazoline parasiticide formulations and methods for treating blepharitis) held by Tarsus Pharmaceuticals, Inc. expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Tarsus Pharmaceuticals, Inc.
Grant date
Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/42, A61K31/422, A61K47/26, A61K9/0048